News | Prostate Cancer | March 01, 2016

Queen's University Leads Irish Trial of New Prostate Cancer Treatment

ADDRAD trial will assess efficacy of volumetric modulated arc therapy and radium 223 to more specifically target advanced-stage disease

prostate cancer, ADDRAD trial, Ireland, VMAT and radium 223

March 1, 2016 — Queen’s University Belfast, in partnership with the Belfast Trust, is leading the world’s first ever trial of a new combination of cancer therapies for patients with advanced prostate cancer, with the hope of prolonging their lives.

The ADRRAD trial, which recently started at the Northern Ireland Cancer Centre, is funded by and supported by Friends of the Cancer Centre and Bayer Pharmaceuticals.

In 2014 there were over 1,100 newly diagnosed cases of prostate cancer in Northern Ireland. Almost 8,500 men there are living with a diagnosis of prostate cancer, and just under 250 men each year die as a result of the illness.

Thirty patients will participate in the trial over the next 18 months. It is aimed at men with advanced prostate cancer, where the cancer has spread to the bones at the time of diagnosis. This accounts for around 10 percent of prostate cancer patients.

Men with advanced prostate cancer are normally treated with hormone therapy, which aims to shrink a tumor by limiting the amount of testosterone reaching the cancer cells. The new approach being trialed by Queen’s researchers is the first to combine two existing forms of radiotherapy — volumetric modulated arc therapy (VMAT) to target prostate cancer cells in the pelvis, along with radium 223 to target the disease in the bones. If successful, it has the potential to completely change the way in which the disease is treated and potentially extend the life expectancy of patients with the advanced stages of the disease.

VMAT is an advanced type of radiation therapy which manipulates radiation beams to conform to the shape of a tumor, delivering precise radiation doses to a tumor, while minimizing the dose to surrounding normal tissue. It is delivered externally, using a radiotherapy machine called a linear accelerator

Radium 223 is a relatively new ‘bone-seeker’ drug. It is a type of internal radiotherapy, which is given intravenously. Once it is in the bones, radium 223 releases radiation which travels a very short distance — between 2 and 10 cells deep, which is less than a millimeter. This means it delivers a high dose of radiation close to the tumor deposits in the bone, killing the cancer cells and minimizing damage to the healthy cells.

Prof. Joe O’Sullivan from Queen’s University’s Centre for Cancer Research and Cell Biology and clinical director of oncology in Belfast Trust is leading the trial at the Northern Ireland Cancer Centre at Belfast City Hospital. He said: “This is the first trial of its kind anywhere in the world. It is hoped that combining the two forms of radiotherapy will be more effective than existing hormone treatment in targeting prostate cancer cells at multiple sites and extend the life expectancy of men whose treatment options are otherwise limited. We expect results from the initial trial within two years, with the view to then embarking on a larger trial with a greater number of patients.

“This trial is a crucial development in the fight against prostate cancer, which is the most common type of cancer among men in Northern Ireland. Three men here are diagnosed with this disease every day. Thousands are living with the illness, which unfortunately claims one life every hour across the U.K. Queen’s, Belfast Trust and Northern Ireland are at the forefront of global efforts to develop more effective treatments for all types of cancer. The ADRRAD trial is an excellent example of the potentially life-changing and life-saving impact of this work.”

The ADRRAD trial is sponsored by Belfast Health and Social Care Trust. Scientific work which takes place alongside the trial is supported by Prostate Cancer UK and the Movember Foundation as part of the Belfast-Manchester Movember Centre of Excellence – a partnership between Queen’s and the University of Manchester.

Iain Frame, M.D., director of research at Prostate Cancer UK said: “This trial represents a really exciting shift in how we think about prostate cancer – away from aiming to prolong life for men with advanced prostate cancer, towards taking the first steps to stopping the disease in its tracks once and for all. The scale of what we can achieve when we work together as funders, clinicians, scientists and men must not be underestimated. We are on the brink of remarkable breakthroughs in prostate cancer research, and this trial could be one of them.

“That’s why we mustn’t falter now. If we continue investing in world class research like this, within ten years, the world of prostate cancer research and treatment will be a far more hopeful place for men with and at high risk of the disease.”

For more information: www.qub.ac.uk

Related Content

Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Study Assesses Risk of MRI Exams for Patients With Tattoos
News | Magnetic Resonance Imaging (MRI) | February 01, 2019
A new European study concluded that magnetic resonance imaging (MRI) exams pose little risk for people with tattoos,...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.